Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options

NCT00240552 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT00240552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00240552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options
Lead sponsor
ViiV Healthcare
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2003
Completion date
August 31, 2005
Enrollment
85 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus